Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of ($0.1450) per share and revenue of $0.25 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Nautilus Biotechnology Trading Up 1.6%

Shares of NAUT opened at $2.62 on Friday. Nautilus Biotechnology has a twelve month low of $0.62 and a twelve month high of $4.31. The stock’s 50 day moving average is $2.90 and its two-hundred day moving average is $2.21. The firm has a market capitalization of $331.59 million, a PE ratio of -5.57 and a beta of 1.08.

Insider Buying and Selling at Nautilus Biotechnology

In related news, CEO Sujal M. Patel purchased 25,000 shares of the stock in a transaction dated Wednesday, March 4th. The shares were acquired at an average cost of $2.61 per share, with a total value of $65,250.00. Following the purchase, the chief executive officer directly owned 10,366,721 shares in the company, valued at $27,057,141.81. This trade represents a 0.24% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 41.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in NAUT. Bank of America Corp DE grew its stake in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after purchasing an additional 13,363 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Nautilus Biotechnology in the 1st quarter worth approximately $194,000. Acadian Asset Management LLC grew its holdings in shares of Nautilus Biotechnology by 468.3% in the 1st quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after acquiring an additional 50,871 shares during the period. XTX Topco Ltd increased its stake in Nautilus Biotechnology by 86.2% in the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock valued at $48,000 after purchasing an additional 30,641 shares in the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Nautilus Biotechnology in the 2nd quarter valued at approximately $45,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Guggenheim increased their target price on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research note on Tuesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.00.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.